A Proof-of-Concept Study for Ilorasertib (ABT-348) Activity in Patients With CDKN2A-Deficient Advanced Solid Cancers: a Phase II Basket Trial
Phase of Trial: Phase II
Latest Information Update: 30 Aug 2017
At a glance
- Drugs Ilorasertib (Primary)
- Indications Solid tumours
- Focus Proof of concept; Therapeutic Use
- 22 Aug 2016 Status changed from not yet recruiting to recruiting.
- 05 Aug 2016 Planned primary completion date changed from 1 Oct 2022 to 1 Aug 2022.
- 05 Aug 2016 Planned initiation date changed from 1 Oct 2016 to 1 Aug 2016.